一分钟看懂
这是一项关于结直肠癌的III 期研究，登记的药物或干预包括Enlituo®；Erbitux®，当前状态为招募中。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Enlituo®；Erbitux® · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-Sen University Cancer Center · 广州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Voluntarily participate in the study and sign the informed consent form.
- * Aged 18 years or older.
- * Participants with histologically and/or cytologically confirmed locally advanced/metastatic colorectal cancer.
- * Have at least one evaluable or measurable tumor target lesion (RECIST v1.1). Lesions that have received previous local therapy or locoregional therapy (e.g., radiotherapy, hepatic arterial embolization, radiofrequency ablation, and percutaneous intervention) should not be considered measurable lesions unless progression is observed after the local or locoregional therapy.
- * Have not received prior systemic anti-tumor therapy for locally advanced/metastatic colorectal cancer. Previous neoadjuvant or adjuvant therapy for colorectal cancer is allowed if completed ≥6 months before the detection of disease recurrence or metastasis.
- * Have an ECOG performance status of 0 or 1.
- * Have a life expectancy of ≥12 weeks.
- * Have locally advanced/metastatic colorectal cancer confirmed by a local laboratory to be RAS/BRAF wild-type and MSS/pMMR.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07595276；登记信息更新于 2026-10-05；本站同步于 2026-10-08，中国中心当前名额未经人工确认。